Bright Minds Biosciences Inc. DRUG
51.80
(1.71)
(3.20%)
as of 25 Sep
- Market cap
- $527.8M
- P/E
- 0.0×
Follow DRUG
| Sep '17 | Sep '19 | Sep '20 | Dec '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 2.18 | 31.38 | 31.38 | 31.38 | 8.11 | 24.25 | 11.33 | 36.10 |
Net Debt/EBITDA |
— | 1.02 | 7.99 | 7.99 | 2.25 | 0.77 | 0.92 | 2.07 | 5.98 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.60% | 0.00% | 0.65% | 0.05% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.53 | 0.03 | 0.00 | 0.85 | 0.91 | 0.95 | 0.66 | 0.71 |
Capex/Depreciation |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (18.59%) | 190.38% | 93.93% | (169.76%) | (99.25%) | (83.16%) | (45.96%) | (27.88%) | |
| — | (95.98%) | (85.66%) | (43.17%) | (43.17%) | (92.53%) | (75.07%) | (42.96%) | (26.97%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (181.76%) | (44.59%) | (44.59%) | (44.59%) | (142.85%) | (112.87%) | (51.33%) | (14.92%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.02) | (0.17) | — | (3.23) | (4.31) | (1.40) | (0.32) | (0.90) |
Cash per Share |
— | 0.05 | 12.21 | 0.00 | 8.71 | 3.69 | 1.35 | 0.98 | 8.62 |
Shareholders Equity per Share |
— | 0.08 | 11.99 | 0.00 | 8.56 | 3.34 | 1.32 | 0.94 | 8.53 |
Interest Debt per Share |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.08 | 11.99 | 0.00 | 8.56 | 3.34 | 1.32 | 0.94 | 8.53 |
Free Cash Flow |
— | (0.03) | (0.22) | — | (5.79) | (10.64) | (5.21) | (1.36) | (6.21) |
Working Capital |
— | 0.03 | 15.36 | 15.36 | 15.36 | 8.20 | 4.84 | 4.01 | 58.60 |
Net Current Asset Value |
— | 0.03 | 15.36 | 15.36 | 15.36 | 8.15 | 4.84 | 3.98 | 58.57 |
| Other line items | |||||||||
Quick Ratio |
— | 2.18 | 31.12 | 31.12 | 31.12 | 8.00 | 24.15 | 10.92 | 35.68 |
Depreciation/Fixed assets |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
— | (20.26%) | (0.69%) | 0.00% | (18.69%) | (61.09%) | (52.63%) | (16.38%) | (5.27%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Revenue per Share |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.02) | (0.17) | — | (3.23) | (4.31) | (1.40) | (0.32) | (0.90) |
Capex per Share |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 0.09 | 0.09 | 0.10 | 0.07 | 0.03 | 0.17 |
Average Payables |
— | — | — | — | — | 0.80 | 0.63 | 0.24 | 0.97 |
Average Assets |
— | 0.06 | 7.99 | 15.86 | 15.86 | 12.66 | 7.28 | 4.79 | 32.42 |
Average Common Equity |
— | 0.32 | (3.60) | (7.29) | 4.03 | 11.81 | 6.57 | 4.48 | 31.36 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates